Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:47:35.994Z.
Calculation as of: 2026-10-06T15:47:35.994Z.
Quote observation: 2026-10-06T15:43:42.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f827d960650d67e3900ac6098f04a5e2078fd3b8121965df68c70cd2fd602cdf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$217.70M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$216.19M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$215.04M
Price/FCF Ratio
37.90
TTM Avg
48.24
3Y Avg
64.03
5Y Avg
64.30
Market Cap
$226.43M
Price/FCF Ratio
N/A
TTM Avg
9.31
3Y Avg
9.38
5Y Avg
9.38
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $217.70M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $219.27M | N/A | 3.22 | 3.23 | 4.48 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.19M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $215.58M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $215.13M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $215.04M | 37.90 | 48.24 | 64.03 | 64.30 |
| Keros Therapeutics, Inc. (KROS)vs › | $226.43M | N/A | 9.31 | 9.38 | 9.38 |
| Pro-Dex, Inc. (PDEX)vs › | $207.89M | 30.16 | 28.19 | 28.69 | 27.64 |
| Profound Medical Corp. (PROF)vs › | $228.93M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $231.59M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
